Skip to main content
Log in

Differential diagnosis and management of acute profound thrombocytopenia by tirofiban : A case report

  • Case Report
  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Summary

Although the glycoprotein IIb/IIIa receptor inhibitors have improved outcomes of patients with acute coronary syndrome (ACS), therapy with these agents may cause thrombocytopenia with bleeding complications. This adverse effect is seemed to be rare with tirofiban. In this report, we describe a case of acute profound thrombocytopenia within two hours of tirofiban administration and review the differential diagnosis and the management of thrombocytopenia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Boersma E, Harrington EA, Moliterno DJ, et al. (2002) Platelet glycoprotein IIb/IIIa inhibi-tors in acute coronary syndromes: a meta-analysis of all majr randomized trials. Lancet 359:189–198

    Article  PubMed  CAS  Google Scholar 

  2. Karvouni E, Katritsis DG, Ioannidis J (2003) Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol 41:26–32

    Article  PubMed  CAS  Google Scholar 

  3. RESTORE Investigators (1997) Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 96:1445–1453

    Google Scholar 

  4. PRISM Study Investigators (1998) A comparision of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 338:1498–1505

    Article  Google Scholar 

  5. PRISM-PLUS Study Investigators (1998) Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non Q-wave myocardial infarction. N Engl J Med 338:1488–1497

    Article  Google Scholar 

  6. Bougie DW, Wilker PR, Wuitschick ED, et al. (2002) Acute thrombocytopenia after treatment with tirofiban or ebtifibatide is associated with antibodies spesific for ligand-occupied GPIIb/IIIa. Blood 100:2071–2076

    PubMed  CAS  Google Scholar 

  7. BednarB, Cook JJ, Holahan MA, et al. (1999) Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa. Blood 94:587–599

    PubMed  CAS  Google Scholar 

  8. Berkowitz SD, Harrington RA, Rund MM, et al. (1997) Acute profound thrombocytopenia after c7E3 Fab (Abciximab) therapy. Circulation 95:809–813

    PubMed  CAS  Google Scholar 

  9. Holmes HB, Kabbani S, Watkins M, et al. (2000) Abciximab-associated pseudothrom-bocytopenia. Circulation 101:938–939

    PubMed  CAS  Google Scholar 

  10. Warkentin TE, Aird WC, Rand JH (2003) Platelet-endothelial intereactions:sepsis, HIT and antiphospholipid syndrome. Hematology 497–519

  11. Warkentin TE, Kelton JG (2001) Temporal aspects of heparin-induced thrompocytopenia. N Engl J Med 344:1286–1292

    Article  PubMed  CAS  Google Scholar 

  12. Llevadot J, Coulter SA, Giugliano RP (2000) A practical approach to diagnosis and management of thrombocytopenia associated with glycoprotein IIb/IIIa receptor inhibitors. J Thromb Thrombolysis 9:175–180

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Burcu Demirkan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Demirkan, B., Guray, Y., Guray, U. et al. Differential diagnosis and management of acute profound thrombocytopenia by tirofiban : A case report. J Thromb Thrombolysis 22, 77–78 (2006). https://doi.org/10.1007/s11239-006-7789-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-006-7789-1

Keywords

Navigation